1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Familial Adenomatous Polyposis Coli - Pipeline Review, H1 2014

Familial Adenomatous Polyposis Coli - Pipeline Review, H1 2014

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 42 pages

Familial Adenomatous Polyposis Coli - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Familial Adenomatous Polyposis Coli - Pipeline Review, H1 2014’, provides an overview of the Familial Adenomatous Polyposis Coli’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Familial Adenomatous Polyposis Coli, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Adenomatous Polyposis Coli and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis Coli
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Familial Adenomatous Polyposis Coli and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Familial Adenomatous Polyposis Coli products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Familial Adenomatous Polyposis Coli pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Familial Adenomatous Polyposis Coli
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis Coli pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Familial Adenomatous Polyposis Coli - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Familial Adenomatous Polyposis Coli Overview 6
Therapeutics Development 7
Pipeline Products for Familial Adenomatous Polyposis Coli - Overview 7
Pipeline Products for Familial Adenomatous Polyposis Coli - Comparative Analysis 8
Familial Adenomatous Polyposis Coli - Therapeutics under Development by Companies 9
Familial Adenomatous Polyposis Coli - Therapeutics under Investigation by Universities/Institutes 10
Familial Adenomatous Polyposis Coli - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Familial Adenomatous Polyposis Coli - Products under Development by Companies 14
Familial Adenomatous Polyposis Coli - Products under Investigation by Universities/Institutes 15
Familial Adenomatous Polyposis Coli - Companies Involved in Therapeutics Development 16
Marina Biotech, Inc. 16
S.L.A. Pharma AG 17
Cancer Prevention Pharmaceuticals, Inc. 18
Familial Adenomatous Polyposis Coli - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
icosapent - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
eflornithine hydrochloride + sulindac - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
aspirin - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
CEQ-508 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
CEQ-501 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Familial Adenomatous Polyposis Coli - Recent Pipeline Updates 34
Familial Adenomatous Polyposis Coli - Dormant Projects 38
Familial Adenomatous Polyposis Coli - Product Development Milestones 39
Featured News and Press Releases 39
Dec 05, 2013: Phase III Familial Adenomatous Polyposis Trial Now Open for Enrollment 39
Apr 12, 2011: Pfizer Announces Encouraging Data From Open-Label Extension Study Of Tafamidis 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables

Number of Products under Development for Familial Adenomatous Polyposis Coli, H1 2014 7
Number of Products under Development for Familial Adenomatous Polyposis Coli - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Familial Adenomatous Polyposis Coli - Pipeline by Marina Biotech, Inc., H1 2014 16
Familial Adenomatous Polyposis Coli - Pipeline by S.L.A. Pharma AG, H1 2014 17
Familial Adenomatous Polyposis Coli - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Assessment by Combination Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Familial Adenomatous Polyposis Coli Therapeutics - Recent Pipeline Updates, H1 2014 34
Familial Adenomatous Polyposis Coli - Dormant Projects, H1 2014 38

List of Figures

Number of Products under Development for Familial Adenomatous Polyposis Coli, H1 2014 7
Number of Products under Development for Familial Adenomatous Polyposis Coli - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Related Market Segments :

Therapy
Pharmaceutical
Cancer

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.